BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32299816)

  • 1. A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.
    Wei W; Lin Y; Song Z; Xiao W; Chen L; Yin J; Zhou Y; Barta SK; Petrus M; Waldmann TA; Yang Y
    Clin Cancer Res; 2020 Aug; 26(15):4093-4106. PubMed ID: 32299816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.
    Song Z; Wei W; Xiao W; Al-Saleem ED; Nejati R; Chen L; Yin J; Fabrizio J; Petrus MN; Waldmann TA; Yang Y
    Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28980-28991. PubMed ID: 33139544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
    Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
    Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
    Tien FM; Tsai CH; Liu JH; Lin CT
    J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
    Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
    J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
    Shao C; Liu J; Zhou W; Raut MK; Monberg M; Cao X; Ricart AD; Balakumaran A
    Leuk Lymphoma; 2019 Apr; 60(4):947-954. PubMed ID: 30234407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
    Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
    Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
    Bonthapally V; Wu E; Macalalad A; Yang H; Shonukan O; Liu Y; Chi A; Huebner D
    Curr Med Res Opin; 2015 May; 31(5):993-1001. PubMed ID: 25772232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.